SCHEMBL5543941

SCHEMBL5543941

[CH2]CCc1ccc(OS(C)(=O)=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.44
PPARG P37231 2/20 0.44
MMP2 P08253 2/20 0.41
MMP7 P09237 2/20 0.41
MMP9 P14780 2/20 0.41
MMP14 P50281 2/20 0.41
MMP1 P03956 1/20 0.41
STS P08842 1/20 0.41
KDM4E B2RXH2 3/20 0.39
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
ALDH1A1 P00352 3/20 0.38
CA12 O43570 3/20 0.38
CA2 P00918 3/20 0.38
GAA P10253 2/20 0.38
CA1 P00915 1/20 0.38
CA5A P35218 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
APLNR P35414 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542632 0.89 PPARA (0.47) PPARAPPARGMMP2MMP7MMP9
SCHEMBL5539666 0.87 PPARA (0.49) PPARAPPARGMMP2MMP7MMP9
SCHEMBL5543027 0.86 PPARA (0.50) PPARAPPARGMMP2MMP7MMP9
SCHEMBL2000362 0.84 STS (0.44) PPARAPPARGMMP2MMP7MMP9
SCHEMBL1994623 0.81 TAAR1 (0.57) PPARAPPARGSTSCA12CA2
SCHEMBL5994202 0.81 PPARA (0.49) PPARAPPARGMMP2MMP7MMP9
SCHEMBL980257 0.81 PPARA (0.44) PPARAPPARGMMP2MMP7MMP9
SCHEMBL3838706 0.79 STS (0.63) PPARAPPARGMMP2MMP7MMP9
SCHEMBL979920 0.79 PPARA (0.49) PPARAPPARGMMP2MMP7MMP9
SCHEMBL3655208 0.79 CA2 (0.53) PPARAPPARGSTSKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
CN-1312795-A Novel 3-arylpropionic acid derivatives and analogs thereof ASTRA ZENECA AKTIEBOLAG (SE) 2001-09-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PPARA 429/4885PPARG 856/4885MMP2 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.